Cargando…

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer

Eph receptors constitute the largest family of receptor tyrosine kinases in the human genome. EphA2 is one prominent member that is overexpressed and functionally altered in many invasive cancers, including pancreatic cancer. Dasatinib, which is a multi-targeted kinase inhibitor mainly developed for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Q, Jorgensen, C, Pawson, T, Hedley, D W
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567084/ https://www.ncbi.nlm.nih.gov/pubmed/18797457 http://dx.doi.org/10.1038/sj.bjc.6604676

Ejemplares similares

The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome
por: Kumar, S R, et al.
Publicado: (2007)

The efficacy of receptor tyrosine kinase EphA2 autophosphorylation increases with EphA2 oligomer size
por: Zapata-Mercado, Elmer, et al.
Publicado: (2022)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
por: Yu, H, et al.
Publicado: (2015)

Progranulin and the receptor tyrosine kinase EphA2, partners in crime?
por: Chitramuthu, Babykumari, et al.
Publicado: (2016)

Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery
por: PosthumaDeBoer, J, et al.
Publicado: (2013)

Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours
por: Green, J, et al.
Publicado: (2006)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas
por: Farace, P, et al.
Publicado: (2009)

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
por: Pichot, C S, et al.
Publicado: (2009)

The catalytically defective receptor protein tyrosine kinase EphA10 promotes tumorigenesis in pancreatic cancer cells
por: Shin, Won‐Sik, et al.
Publicado: (2020)

A Novel Occulta-Type Spina Bifida Mediated by Murine Double Heterozygotes EphA2 and EphA4 Receptor Tyrosine Kinases
por: Abdullah, Nor Linda, et al.
Publicado: (2017)

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
por: Cao, P, et al.
Publicado: (2009)

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis
por: Koreckij, T, et al.
Publicado: (2009)

Inhibition of EphA2 by Dasatinib Suppresses Radiation-Induced Intestinal Injury
por: Kim, Areumnuri, et al.
Publicado: (2020)

Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1
por: Xu, Li, et al.
Publicado: (2017)

EphA1 receptor tyrosine kinase is localized to the nucleus in rhabdomyosarcoma from multiple species
por: LaCombe, Ronnie, et al.
Publicado: (2022)

Dimerization of the EphA1 Receptor Tyrosine Kinase Transmembrane Domain: Insights into the Mechanism of Receptor Activation
por: Chavent, Matthieu, et al.
Publicado: (2014)

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours
por: Baro, M, et al.
Publicado: (2014)

The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence
por: Sun, C K, et al.
Publicado: (2007)

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2017)

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
por: Fischel, J-L, et al.
Publicado: (2005)

The intracellular domains of the EphB6 and EphA10 receptor tyrosine pseudokinases function as dynamic signalling hubs
por: Liang, Lung-Yu, et al.
Publicado: (2021)

Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion
por: Ma, P C, et al.
Publicado: (2007)

Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer
por: Li, Meng, et al.
Publicado: (2017)

Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival
por: Gajdzis, Malgorzata, et al.
Publicado: (2020)

Receptor Tyrosine Kinase EphA5 Is a Functional Molecular Target in Human Lung Cancer
por: Staquicini, Fernanda I., et al.
Publicado: (2015)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
por: Morgillo, F, et al.
Publicado: (2011)

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
por: Konings, I R H M, et al.
Publicado: (2010)

Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours
por: Beloueche-Babari, M, et al.
Publicado: (2015)

Upregulation of calcium-sensing receptor and mitogen-activated protein kinase signalling in the regulation of growth and differentiation in colon carcinoma
por: Bhagavathula, N, et al.
Publicado: (2005)

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib
por: Courtin, Aurelie, et al.
Publicado: (2016)

Receptor tyrosine kinase EphA7 is required for interneuron connectivity at specific subcellular compartments of granule cells
por: Beuter, Simone, et al.
Publicado: (2016)

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
por: Lohse, I, et al.
Publicado: (2015)

The EphA1 and EphA2 Signaling Modulates the Epithelial Permeability in Human Sinonasal Epithelial Cells and the Rhinovirus Infection Induces Epithelial Barrier Dysfunction via EphA2 Receptor Signaling
por: Shin, Jae Min, et al.
Publicado: (2023)

Protein kinase A can block EphA2 receptor–mediated cell repulsion by increasing EphA2 S897 phosphorylation
por: Barquilla, Antonio, et al.
Publicado: (2016)

EphA5 and EphA6: regulation of neuronal and spine morphology
por: Das, Gitanjali, et al.
Publicado: (2016)

EphA4 Receptor Tyrosine Kinase Is a Modulator of Onset and Disease Severity of Experimental Autoimmune Encephalomyelitis (EAE)
por: Munro, Kathryn M., et al.
Publicado: (2013)

Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin
por: Shang, Xiying, et al.
Publicado: (2014)

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation
por: Loriot, Y, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bu6t9fopmb7sf07l8bqr0ct7co